Crinetics Pharmaceuticals (CRNX) Interest & Investment Income (2017 - 2026)

Crinetics Pharmaceuticals' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $12.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 14.63% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $26.5 million (down 14.74% YoY), while the FY2025 annual figure was $1.1 million, down 97.41% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $12.7 million, up from -$206000.0 in the prior quarter.
• The five-year high for Interest & Investment Income was $14.8 million in Q1 2025, with the low at -$6.0 million in Q4 2022.
• The 5-year median for Interest & Investment Income is $1.4 million (2023), against an average of $3.6 million.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income plunged 7552.5% in 2022, then jumped 4057.35% in 2025.
• Crinetics Pharmaceuticals' Interest & Investment Income stood at -$6.0 million in 2022, then jumped by 69.71% to -$1.8 million in 2023, then soared by 895.57% to $14.4 million in 2024, then slumped by 101.43% to -$206000.0 in 2025, then jumped by 6247.57% to $12.7 million in 2026.
• Business Quant data shows CRNX's Interest & Investment Income at $12.7 million in Q1 2026, -$206000.0 in Q4 2025, and $594000.0 in Q3 2025.